Digestive Diseases and Sciences

, Volume 50, Issue 3, pp 533–537 | Cite as

Clinical Management of Hepatic Malignancies: Ferucarbotran-Enhanced Magnetic Resonance Imaging Versus Contrast-Enhanced Spiral Computed Tomography

  • Riccardo Lencioni
  • Clotilde Della Pina
  • Jordi Bruix
  • Pietro Majno
  • Luigi Grazioli
  • Giovanni Morana
  • Antonella Filippone
  • Andrea Laghi
  • Carlo Bartolozzi


This study compares ferucarbotran-enhanced magnetic resonance (MR) imaging with spiral computed tomography (CT) in the clinical management of patients with suspected hepatic malignancy. One hundred fifty-nine patients with suspected liver malignancy were included in a prospective, multicenter, phase IIIB clinical trial. Patients were examined with baseline plus contrast-enhanced spiral CT and with baseline plus ferucarbotran-enhanced MR imaging. For each patient, four maps of liver lesions were constructed by a trusted blind party on the basis of (a) baseline plus contrast-enhanced spiral CT, (b) baseline MR imaging, (c) baseline plus ferucarbotran-enhanced MR imaging, and (d) final diagnosis. Three blinded experts evaluated the treatment options for each map. The concordance of the treatment choice based on imaging with the treatment choice based on final diagnosis was verified. The final therapeutic decision was radical therapy for 85 patients, palliative therapy for 49 patients, and no treatment for 25 patients who had a final diagnosis of benign lesion. Proper treatment allocation was achieved in 121 (76%) of 159 patients when the evaluation was based on liver maps obtained from spiral CT, in 97 (61%) of 159 patients when the evaluation was based on liver maps obtained from baseline MR imaging, and in 136 (85%) of 159 patients when the evaluation was based on liver maps obtained from baseline plus ferucarbotran-enhanced MR imaging. MR imaging with ferucabotran was significantly superior to spiral CT for correct treatment allocation (P = 0.0167). Ferucarbotran-enhanced MR imaging is superior to spiral CT in clinical management of patients with suspected hepatic malignancy.


hepatocellular carcinoma liver metastases magnetic resonance imaging. 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, Christensen E, EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35:421–430, 2001Google Scholar
  2. 2.
    Lencioni R, Cioni D, Crocetti L, Della Pina C, Bartolozzi C: Magnetic resonance imaging of liver tumors. J Hepatol 40:162–171, 2004Google Scholar
  3. 3.
    Ward J, Naik KS, Guthrie JA, Wilson D, Robinson PJ: Hepatic lesion detection: comparison of MR imaging after the administration of superparamagnetic iron oxide with dual-phase CT by using alternative-free response receiver operating characteristic analysis. Radiology 210:459–466, 1999PubMedGoogle Scholar
  4. 4.
    Mori K, Scheidler J, Helmberger T, et al.: Detection of malignant hepatic lesions before orthotopic liver transplantation: accuracy of ferumoxides-enhanced MR imaging. AJR Am J Roentgenol 179:1045–1051, 2002Google Scholar
  5. 5.
    Kang BK, Lim JH, Kim SH, Choi D, Lim HK, Lee WJ, Lee SJ: Preoperative depiction of hepatocellular carcinoma: ferumoxides-enhanced MR imaging versus triple-phase helical CT. Radiology 226:79–85, 2003PubMedGoogle Scholar
  6. 6.
    Ros PR, Freeny PC, Harms SE, et al.: Hepatic MR imaging with ferumoxide: a multicentric clinical trial of the safety and efficacy in the detection of focal hepatic lesions. Radiology 196:481–488, 1995PubMedGoogle Scholar
  7. 7.
    Ba-Ssalamah A, Heinz-Peer G, Schima W, et al.: Detection of focal hepatic lesions: comparison of unenhanced and SHU 555 A-enhanced MR imaging versus biphasic helical CTAP. J Magn Reson Imaging 11:665–672, 2000CrossRefPubMedGoogle Scholar
  8. 8.
    Vogl TJ, Schwarz W, Blume S, et al.: Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US. Eur Radiol 13:262–272, 2003PubMedGoogle Scholar
  9. 9.
    Reimer P, Balzer T: Ferucarbotran (Resovist): a new clinically approved RES-specific contrast agent for contrast-enhanced MRI of the liver: properties, clinical development, and applications. Eur Radiol 13:1266–1276, 2003PubMedGoogle Scholar
  10. 10.
    Mazzaferro V, Regalia E, Doci R, et al.: Liver transplantation for the treatment of small hepatocellular carcinoma in patients with cirrhosis. N Engl J Med 334:693–699, 1996CrossRefGoogle Scholar
  11. 11.
    Bruix J, Castells A, Bosch J, et al.: Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology 111:1018–1022, 1996Google Scholar
  12. 12.
    Llovet JM, Fuster J, Bruix J: Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30:1434–1440, 1999CrossRefGoogle Scholar
  13. 13.
    Majno PE, Azoulay D, Bismuth H: General surgical aspects and the risks of liver surgery in patients with hepatic disease. In Oxford Textbook of Hepatology. Bircher J, Rizzetto M, Rhodes J, Benhamou JP (eds). Oxford, Oxford University Press, 1999, pp 1997–2008Google Scholar
  14. 14.
    Lencioni R, Bartolozzi C, Caramella D, et al.: Treatment of small hepatocellular carcinoma with percutaneous ethanol injection. Analysis of prognostic factors in 105 Western patients. Cancer 76:1737–1746, 1995PubMedGoogle Scholar
  15. 15.
    Livraghi T, Giorgio A, Marin G, et al.: Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 197:101–108, 1995PubMedGoogle Scholar
  16. 16.
    Lencioni R, Allgaier HP, Cioni D, et al.: Small hepatocellular carcinoma in cirrhosis: randomized comparison of radiofrequency thermal ablation versus percutaneous ethanol injection. Radiology 228:235–240, 2003PubMedGoogle Scholar
  17. 17.
    Llovet JM, Real MI, Montana X, et al.: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734–1739, 2002CrossRefPubMedGoogle Scholar
  18. 18.
    Majno PE, Azoulay D, Bismuth H: Malignant biliary obstruction. In Oxford Textbook of Hepatology. Bircher J, Rizzetto M, Rhodes J, Benhamou JP (eds). Oxford, Oxford University Press, 1999, pp 1530–1545Google Scholar
  19. 19.
    Bismuth H, Majno PE: Hepatobiliary surgery. J Hepatol 32(S1):208–224, 2000PubMedGoogle Scholar
  20. 20.
    Selzner M, Morse MA, Vredenburgh JJ, Meyers WC, Clavien PA: Liver metastases from breast cancer: long-term survival after curative resection. Surgery 127:383–389, 2000Google Scholar
  21. 21.
    Bolton JS, Fuhrman GM: Survival after resection of multiple bilobar hepatic metastases from colorectal carcinoma. Ann Surg 231:743–751, 2000PubMedGoogle Scholar
  22. 22.
    Reimer P, Jahnke N, Fiebich M, et al.: Hepatic lesion detection and characterization: value of nonenhanced MR imaging, superparamagnetic iron oxide-enhanced MR imaging, and spiral CT-ROC analysis. Radiology 217:152–158, 2000PubMedGoogle Scholar
  23. 23.
    Oudkerk M, Torres CG, Song B, et al.: Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT. Radiology 223:517–524, 2002PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Riccardo Lencioni
    • 1
    • 8
  • Clotilde Della Pina
    • 1
  • Jordi Bruix
    • 6
  • Pietro Majno
    • 7
  • Luigi Grazioli
    • 2
  • Giovanni Morana
    • 3
  • Antonella Filippone
    • 4
  • Andrea Laghi
    • 5
  • Carlo Bartolozzi
    • 1
  1. 1.Department of RadiologyUniversity of PisaPisa
  2. 2.Department of RadiologyUniversity of BresciaBrescia
  3. 3.Department of RadiologyUniversity of VeronaVerona
  4. 4.Department of RadiologyG. D’Annunzio UniversityChieti
  5. 5.Department of Radiology“La Sapienza” UniversityRomeItaly
  6. 6.BCLC Group, Liver UnitHospital ClinicBarcelonaSpain
  7. 7.Department of SurgeryUniversity of GenevaGenevaSwitzerland
  8. 8.Department of RadiologyUniversity of PisaPisaItaly

Personalised recommendations